The purpose of this study was to develop a novel drug delivery system of anti-TB drug, Rifabutin, in the form of Inhalable β-glucan micro particles with a view to achieve improved treatment of pulmonary tuberculosis (TB).Specifically, the study aims to investigate the feasibility and efficacy of utilizing inhalable β-glucan microparticles as carriers for rifabutin, a potent antibiotic used in TB therapy. This evidence concerns the gene PPIB and pulmonary tuberculosis.